Background: Psoriasis is the disease of abnormal keratinocyte differentiation and apoptosis. Alterations in DNA methylation leading to keratinocyte hyperproliferation is one of the proposed pathogenic mechanisms of psoriasis. B-cell receptor associated protein (BCAP31) has been reported to be involved in the proliferation and apoptosis of keratinocytes. Up-regulation and changing in BCAP31 promoter methylation has been reported to be associated with some cancers. To date, there has been no study of psoriasis.
Introduction
Psoriasis is a chronic, inflammatory skin disease found in approximately 1-3% of the world's population. 1, 2 The characteristics of psoriasis are inflammation in dermis with abnormal epidermis. 3, 4 The keratinocytes of psoriatic skin lesions reveal hyperproliferation, incomplete differentiation and abnormal apoptosis. Both genetic and environmental factors play roles in the induction and maintenance of disease. 5, 6 Recent cumulative data shown that DNA methylation is one of the main pathogenic mechanisms of psoriasis. Changes in the methylation of retrotransposons and promoters of several genes such as SHP-1, ID4, p15, p21 and p16 ink4a have been reported in psoriasis. [7] [8] [9] [10] B-cell receptor associated protein 31 (BCAP31) is a polytopic endoplasmic reticulum (ER) membrane protein.
The cytoplasmic tail of BCAP31 contains a death effector domain. BCAP31 has roles in the over-expression of MHC class I, and the transport of selected proteins from the ER.
11,12
Both caspase-1 and caspase-8 can cleave BCAP31. The full-length protein of BCAP31 provides anti-apoptotic activity, while the cleaved fragment is presumed to promote apoptosis in the Keratin-forming tumor cell line HeLa (KB cell line) and Human lung carcinoma cell line (H1229 cell line). [13] [14] [15] BCAP31 has been reported to be involved in the proliferation and apoptosis of keratinocytes. For example, BCAP31 binds to
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Methods
Patients and healthy controls
Skin biopsies of ten patients diagnosed with chronic plaque type psoriasis by experienced dermatologist at King Chulalongkorn Memorial Hospital (5 males, 5 females) and 10 normal subjects (2 male, 8 females) were analyzed in the study. The severity of psoriasis was classified according to the Psoriasis Area and Severity Index (PASI). All patients were free from systemic skin therapies for at least 4 weeks or topical skin therapies for at least 2 weeks prior to sample collection. Patients with a familial or personal history of autoimmune disease and cancer were excluded from the study. Normal skin was recruited from elective plastic surgery cases. The study was approved by the ethical committee of the King Chulalongkorn University. All participants provided informed consent. The demographic data are shown in Table 1 .
BCAP31 expression and methylation in psoriasis
87 using a Ventana Benchmark LT automated immunostainer. Normal human lung tissue was used as a positive control, and omission of the primary antibody as a negative control. The staining was assigned as pathologist visual scoring according to the percentage of cells with BCAP31 staining as follows: 0 (no staining), 1 (<10% of cell staining), 2 (10-50% of cell staining), or 3 (>50% of cell staining).
21
Cell isolation
Keratinocytes from paraffin-embedded tissues from 10 patients with psoriasis and 10 normal subjects were separated using The PALM MicroLaser Microdissection System (P.A.L.M. MicroLaser Technologies AG, Burnried, Germany). The micro-dissected keratinocytes were removed from the slide by cutter pulse and collected in a micro-tube.
DNA preparation and Bisulfite-modification
All samples were extracted DNA using QIAamp DNA mini kit™ (QIAGEN). Then, 500 ng of DNA was bisulfite-treated using the EZ DNA methylation Kit™ (Zymo Research, Orange, CA, USA) according to the manufacturer's specifications. The bisulfite-treated DNA samples were stored at -20˚C until use.
Bisulfite Cloning and Sequencing
The methylation status of BCAP31 Promoter was analyzed using bisulfite cloning and sequencing technique as previously described. 22 The amplification was carried out in nested PCR with 2 consecutive primer sets. For nested PCR, 1µL of modified DNA was amplified using first round primers (forward 5'-GTA GGG TTT TTT GGT TAG TAG-3' reverse 5'-ACT ACT ATA AAA AAA TTC ATT AC-3') and second round primers (forward 5'-ATT TTT AGA GGG TAG GAT T-3' reverse 5'-ACT ACT ATA AAA AAA TTC TAT TAC-3'; product size 492 bp). The DNA was amplified by PCR at 95˚C for 4 min followed by 8 cycles of 95˚C for 1 min, 50˚C for 2 min, and 72˚C for 3 min, 30 cycles of 95˚C for 30 sec, 50˚C for 2 min, 72˚C for 1.5 min and final extension at 72˚C for 10 min. The PCR products were separated on a 2% agarose gel and purified by the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). Then, the purified-PCR products were ligated into a pGEM-T-easy vector (Promega). Sequencing of cloned PCR products was done with the ABI Prism BigDye or Dye Terminator cycle sequencing kits (Perkin Elmer, Foster City CA).
Statistical analysis
The overall percentage of methylation of all 46 CpG positions and the percentage of methylation of each CpG position were compared between groups by independent t-test and paired t-test, (sig 2-tailed) respectively, using the SPSS software for windows version 20.0 (SPSS Inc., Chicago, IL, USA). A p-value of < 0.05 was considered to be significant.
Results
Increase BCAP31 protein expression in psoriatic epidermis
All normal skin sections revealed mild to moderate staining of BCAP31 in the epidermis, especially in the lower part, whereas all of the skin sections from patients with psoriasis E5 protein of HPV 16 and 31 to regulate the proliferative ability of HPV-infected keratinocytes. 16 The current study demonstrated that BCAP31 was the target of caspase-1 in UVB-induced apoptosis of keratinocytes. 13 Up-regulation of BCAP31 has been reported in early and advanced hepatocellular carcinoma. 17 Recently, BCAP31 amplification was proved to be correlated with cellular immune response and longer survival in ovarian cancer. 18 Furthermore, BCAP31 promoter methylation has been defined as being associated with hormone receptor status and survival in breast cancer. 19, 20 Abnormal proliferation and apoptosis of keratinocytes is the main pathogenesis of psoriasis, and UVB phototherapy is one of the most effective therapies in psoriasis. Therefore, we investigated BCAP31 protein expression and the methylation status of BCAP31 promoter in keratinocytes from patients with psoriasis compared with normal subjects. These data might clarify a probable mechanism for the abnormal proliferation and apoptosis of keratinocytes in psoriasis and the efficiency of UVB phototherapy in psoriasis. Immunohistochemistry Formalin-fixed skin sections from 8 patients with psoriasis and 5 normal subjects were analyzed by immunohistochemistry technique as previous described. 8 Briefly, tissue section on positively charged glass slides were baked overnight at 60°C and carried by Ventana cell Conditioning 1 solution (Ventana Medical Systems, Tucson, AZ). Then, the tissue sections were microwaved at 900-W for 15 minutes and blocked for endogenous peroxidase and biotin, followed by incubation with antibody against BCAP31 protein (Abcam, Cambridge, MA; at dilution 1:2000). The staining was performed (Figure 1) . The mean pathologist visual score of patients with psoriasis was higher than normal subjects (mean score ± SD of psoriasis vs. normal = 3.0 ± 0 vs. 1.8 ± 1.095). There is no significant correlation between the epidermal thickness and BCAP31 protein expression (data not shown).
Demethylation of BCAP31 promoter in psoriatic keratinocyte
The overall methylation of 46 CpG positions of the BCAP31 promoter of keratinocytes from patients with psoriasis was significantly lower than in normal subjects (% methylation of psoriasis vs. normal = 14.94 vs. 60.61, p = 0.0003) (Figure 2) . The methylation levels of each CpG site (46 CpGs in total) were also compared between psoriasis and normal subjects ( Table  2) . Keratinocytes from psoriatic patients revealed a significantly lower level of methylation of most CpG sites than normal subjects (35 of 46 CpG sites) (p < 0.05). 
Discussion
BCAP31 is an integral membrane protein that is ubiquitously expressed in the ER. It is a member of the Bcl-2 family of proteins that plays an important role in apoptosis. 14, 23 A previous study demonstrated that BCAP31 is a target of high-risk HPV E5 and A4 proteins in HPV-infected keratinocytes and is crucial for sustaining proliferative ability in differentiating cells. 15, 16 Our study demonstrated the increased BCAP31 protein expression in psoriatic keratinocyte compared with normal keratinocyte. A previous study showed that BCAP31 is involved in UVB-induced apoptosis of keratinocytes. Moreover, BCAP31 has been proven to be a target molecule of the E5 protein and plays an important role in the maintenance of proliferative competence of HPV-infected keratinocytes. 16 Abnormal keratinocyte apoptosis is one of the important pathogenic processes of psoriasis. Several reported indicated that alterations in the pro-apoptotic and anti-apoptotic molecules of keratinocytes, such as the up-regulation of Bcl-xL, c-FLIP, and survivin and down-regulation of caspase-9, are the conceivable main mechanisms leading to abnormal keratinocyte apoptosis in psoriasis. Moreover, significant down-regulation of some anti-apoptotic molecules and up-regulation of pro-apoptotic molecules had been observed after psoriatic treatments. [24] [25] [26] Thus, it is possible that increase BCAP31 protein is one of the mechanism controlling abnormal hyperproliferative and abnormal apoptosis of keratinocyte in psoriasis.
DNA Methylation is one of the main epigenetics mechanisms regulating gene expression in many diseases such as cancer, autoimmune and some inflammatory diseases. Current publications illustrated the alterations in global and specific promoter DNA methylation of several genes related to the abnormal proliferation and differentiation of keratinocytes in psoriasis. For instance, hypomethylation of long interspersed element-1 (LINE-1) has been reported to be associated with the down-regulation of several apoptotic genes in keratinocytes of patients with psoriasis. In addition, promoter hypermethylation of inhibitor of differentiation 4 (ID4) was reported to be associated with parakeratosis in psoriatic epidermis. 8, 27 Changes in BCAP31 promoter methylation have been reported to be biomarkers in a number of malignancies. Nevertheless, there is no information about BCAP31 promoter methylation in the other group of diseases. In this study, we firstly demonstrated demethylation of BCAP31 promoter in keratinocyte from patients with psoriasis associated with increased BCAP31 protein expression. Thus, it is likely that increase BCAP31 protein expression in psoriatic keratinocyte, is the consequence of BCAP31 promoter demethylation causing up-regulation of BCAP31 mRNA expression. However, the mechanism of BCAP31 promoter demethylation remains unknown.
In conclusion, the present study demonstrated BCAP31 promoter demethylation, which may be a fundamental mechanism in increased BCAP31 protein expression in keratinocytes from patient with psoriasis. BCAP31 could be involved in a crucial molecular pathogenesis of the hyperproliferation and abnormal apoptosis of psoriatic keratinocytes. Nevertheless, further studies are needed to identify the significant biological relevance of BCAP31 in psoriasis and the mechanism of BCAP31 promoter demethylation, which may provide clues for innovative therapies for psoriasis in the future.
